CUPRIC SULFATE Drug Patent Profile

When do Cupric Sulfate patents expire, and when can generic versions of Cupric Sulfate launch?

Cupric Sulfate is a drug marketed by Abraxis Pharm, Am Regent, and Apotex Corp. and is included in three NDAs.

The generic ingredient in CUPRIC SULFATE is cupric sulfate. Additional details are available on the cupric sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cupric Sulfate

A generic version of CUPRIC SULFATE was approved as cupric sulfate by AM REGENT on December 16^th, 2022.

Summary for CUPRIC SULFATE

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for CUPRIC SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	CUPRIC SULFATE	cupric sulfate	INJECTABLE;INJECTION	019350-001	May 5, 1987		DISCN	Yes	No
Am Regent	CUPRIC SULFATE	cupric sulfate	INJECTABLE;INJECTION	216324-001	Dec 16, 2022		RX	No	Yes
Apotex Corp	CUPRIC SULFATE	cupric sulfate	INJECTABLE;INJECTION	218745-001	Aug 19, 2024		DISCN	No	No

Last updated: July 13, 2026

CUPRIC SULFATE Investment Scenario and Patent/Regulatory Fundamentals Analysis

Cupric sulfate is a multi-purpose inorganic salt used across pharmaceuticals, nutrition, industrial medical devices, and compounding. In the US, the investment relevance hinges less on brand-style IP and more on (1) whether a specific finished dosage form has FDA clearance/approval under a product-specific application and (2) whether Orange Book listings exist for that finished product. For “cupric sulfate” as a substance, the IP position is typically thin at the active ingredient level and dominated by formulation, manufacturing, and labeling-controlled claims tied to specific NDC-labeled products, not a broadly ownable compound patent.

Because the prompt does not specify a particular FDA-approved finished product (brand name, NDC, dosage form, manufacturer), the only investable “fundamentals” that can be stated as hard facts are those that apply to cupric sulfate as a general API: regulatory pathway dependence on intended use, typical lack of active ingredient exclusivity, and the practical reality that competition is usually constrained by compliance (GMP, specifications, contamination control, trace metal limits) rather than by blockbuster-style patent fences.

What is cupric sulfate and where does it generate investable demand?

Answer: Demand concentrates in (a) shortages and seasonal procurement for compounding and institutional use, (b) niche dermatology and wound care protocols where copper ions are used, (c) nutrition and trace mineral supply chains, and (d) manufacturing uses where cupric sulfate functions as a chemical input.

Main medical/clinical use categories

• Trace mineral / nutritional therapy: copper supplementation uses cupric salts.
• Dermatologic and topical protocols: copper ion-based antiseptic or astringent applications appear in formulations used by clinicians (often via compounding rather than as a single FDA-approved brand).
• Wound and topical care: copper-based strategies appear in wound management ecosystems, often through combination products or proprietary formulations.

Commercial reality for investors

• If the product is marketed as a drug (as opposed to a dietary ingredient, device adjunct, or compounding salt), revenue is tied to:
  • FDA status of the specific dosage form (approved drug vs compounding bulk chemical)
  • NDC-level supply reliability and lot-to-lot compliance
  • Purchaser behavior in hospitals and IDNs (preference for known suppliers and low rejection rates)
• If the product is bulk/API or compounding-only, the investment case looks like an industrial materials business, not a patent-driven pharma model.

What patents protect cupric sulfate and how strong is the patent estate?

Answer: For cupric sulfate as an inorganic salt, the patent estate at the compound level is generally not a durable barrier in the way it is for new chemical entities. Investable patent positioning usually exists only at the product-specific level: formulation, stability, manufacturing process, impurity profile, particle size, and method-of-use/labeled indications.

Where patent protection typically concentrates

• Formulation patents
  • stabilizing excipients and salt/hydrate control
  • controlled dissolution rate for topical or oral performance
  • impurity-limits claims tied to manufacturing specifications
• Manufacturing process patents
  • crystallization parameters
  • reduction of lead/arsenic contamination and tight control of trace metals
  • validated purification steps and yield optimization
• Method-of-use and labeling claims
  • specific clinical protocols (where permitted)
  • specific concentration ranges for topical or solution use

Implication for investment screening

• A true “patent moat” investment requires confirmation that:
  • an FDA-approved finished dosage form exists with Orange Book-listed patents, and
  • the asserted/remaining patents cover the dosage form and use the company intends to sell.
• Without an identified finished product and listing set, the base-case assumption for cupric sulfate is: limited compound exclusivity, with competition constrained by quality and regulatory compliance.

What is the Orange Book status of cupric sulfate?

Answer: Orange Book exclusivity and patent listings apply to FDA-approved drug products. For cupric sulfate, the practical Orange Book relevance is only determinable at the specific NDC/finished product level. The active ingredient alone does not create an Orange Book status.

Investor checklist (Orange Book driven)

• Identify whether any NDC labeled “cupric sulfate” is listed.
• Confirm whether the listed patents include:
  • composition/formulation
  • method of use
  • manufacturing process
• Track listed expiration dates, exclusivity codes, and patent types.

When does cupric sulfate lose exclusivity?

Answer: Inorganic salts like cupric sulfate typically do not have new-drug exclusivity timelines unless tied to a specific product approval with exclusivity attached. Exclusivity and patent lockout, if any, is product- and listing-specific.

Exclusivity constructs investors track

• 3-year exclusivity for patent challenges on eligible approvals (only if tied to a qualifying NDA/BLA with relevant conditions)
• 5-year exclusivity for certain pediatric and other statutory regimes (product-specific)
• Orphan, Hatch-Waxman, and pediatric extensions (rarely relevant unless a specific application qualifies)
• Patent expiration on Orange Book listings (must be NDC-specific)

What generic entry risks exist for cupric sulfate?

Answer: Generic entry risk is normally high if the product is sold as an approved multisource drug without active formulation/process barriers. If the commercial offering is compounding or bulk salt, substitution risk is immediate and driven by supplier qualification.

Main substitution vectors

• alternative suppliers meeting pharmacopeial specs
• alternative hydrates/particle size profiles that still meet compendial limits
• price pressure in hospital procurement
• rebranding of the same salt into different dosage or topical concentration formats

What formulation patents protect cupric sulfate products and dosage forms?

Answer: When formulation patents exist, they usually protect:

• Topical solutions/solutions for irrigation
• Oral dosage forms (rare as standalone, more often as ingredient in combination)
• Controlled release or stability-optimized compositions
• Hydrate form control and impurity specifications

Common manufacturing and quality control barriers

• Trace metal contamination management (lead, arsenic)
• Controlled hydration and physical form stability
• Tight specification release testing and stability-indicating methods
• GMP batch consistency to avoid out-of-spec rejection in institutional channels

What biosimilar or biologics risk applies to cupric sulfate?

Answer: None directly. Cupric sulfate is not a biologic, and it does not have biosimilar pathways.

What FDA regulatory status applies to cupric sulfate?

Answer: Regulatory status depends on the product category:

• Approved drug product (NDA/ANDA) if marketed as a drug with approved labeling and dosage form.
• Compounding or bulk chemical if used outside approved drug marketing for individual patient needs.
• Nutritional or dietary ingredient if marketed as supplement (different framework than drug).
• Device adjunct only if claims are limited to device functions and do not cross into drug therapeutic claims.

Investor implication

• The most investable pathway is usually:
  • an approved drug product with an identifiable NDC and regulatory file
• If the business is mostly bulk or compounding, the investment case is closer to commodity plus compliance.

Which companies are challenging cupric sulfate sales and where are price pressures highest?

Answer: Without an identified NDC/approved product, company-level competitive attribution cannot be stated as fact. In general, the competitive set for inorganic salts is broad:

• multiple chemical suppliers
• multiple pharma formulators who package the salt into solutions
• compounding pharmacies and outsourcing sterile compounding providers (for topical/irrigation protocols)

Where margins compress fastest

• commodity-like bulk sales
• hospital tenders with multi-lot qualification
• seasons with increased substitution options

How does cupric sulfate compare with other copper salts as an investment?

Answer: Substitution across copper salts (e.g., copper gluconate, copper sulfate pentahydrate, copper chloride) depends on:

• pharmacopoeial acceptability and purchaser preference
• solubility profile and stability in the marketed dosage form
• labeling and formulary inclusion for specific indications

Investment takeaway

• If a product’s value is tied to a specific copper salt’s functional performance in a defined dosage form, then IP and formulation control may matter.
• If it is tied to price and specification, copper salt switching is easy and margins are structurally exposed.

What manufacturing and IP barriers slow down competitors for cupric sulfate?

Answer: Competitive delays typically come from compliance and supply chain, not from compound-level IP.

Operational barriers investors underwrite

• GMP capability to consistently hit impurity specs
• validated methods for hydrate/physical form control
• regulatory inspection readiness (sterile manufacturing if applicable)
• logistics and temperature/humidity control for stable packaging

Litigation and Paragraph IV challenges: is there an FDA patent challenge risk?

Answer: Paragraph IV litigation requires a specific Orange Book-listed ANDA/NDA ecosystem. For cupric sulfate without an identified FDA-approved product and its Orange Book listings, Paragraph IV risk cannot be asserted as a factual scenario.

Key practical investment scenario frameworks for cupric sulfate

Scenario 1: Bulk/API or compounding supply

• Driver: supply reliability and price
• Risk: commodity compression; customer tendering; spec failures
• Moat: QC, delivery performance, and regulatory inspection track record

Scenario 2: Packaged approved drug product

• Driver: NDC-level market access, procurement, and rebate dynamics
• Risk: generic erosion if Orange Book patents are absent or weak
• Moat: product-specific patents and/or exclusivity (must be NDC-confirmed), plus manufacturing validation

Scenario 3: Specialty topical/solution formulation

• Driver: clinical protocol adoption and prescriber/hospital formulary inclusion
• Risk: fast substitution if multiple copper-salt formulations meet specs
• Moat: formulation IP, clinical data, and regulatory defensibility of claims

Investment “fundamentals” map: what to diligence (if this is an investable program)

Answer: For cupric sulfate specifically, diligence should be structured around product status and listing defensibility.

1. Identify the finished product (brand or generic) by NDC and dosage form.
2. Run Orange Book for that NDC: list patents and expiries, and confirm patent coverage types.
3. Map exclusivity (if any) tied to the NDA/BLA.
4. Quantify competitive headwinds:
   • number of AB-rated equivalents (ANDA-style)
   • number of qualified suppliers for the same salt/spec
5. Underwrite quality and supply risk:
   • impurity specifications and failure history
   • validated manufacturing and stability
6. Assess commercial path:
   • hospital tenderability vs specialty stocking
   • rebate and contracting exposure

Key Takeaways

• Cupric sulfate’s investment profile is typically not an innovation-led, patent-driven blockbuster model; it is a product-specific compliance and formulation-dependent business unless an identified FDA-approved finished product has Orange Book patent listings with remaining term.
• Patent “moats,” if present, usually attach to formulation, manufacturing process, and dosage-form-specific claims, not to the inorganic salt itself.
• The dominant risk for cupric sulfate is substitution and price pressure when products are treated as specification-driven inputs.
• The highest-confidence investability assessment requires tying “cupric sulfate” demand to a specific NDC/finished dosage form and then validating Orange Book status and remaining patent term.

FAQs

1) Is cupric sulfate an FDA-approved drug or a compendial chemical used for compounding?
It depends on the marketed product’s dosage form and labeling. The substance alone is not determinative; product classification is.

2) Are patents on copper salts enough to protect cupric sulfate sales from generics?
Usually not at the compound level. Protection, when available, is commonly formulation/process and NDC-specific.

3) What are the main causes of supply failures for cupric sulfate products?
Impurity specification excursions and physical form or hydrate variability are typical drivers, alongside GMP batch rejection risk.

4) Do Paragraph IV challenges apply to cupric sulfate?
Only if there is a specific approved product with Orange Book-listed patents and a corresponding generic filing under Hatch-Waxman.

5) How should investors value cupric sulfate businesses in the absence of strong IP?
Value is usually driven by supply reliability, contracting power, QC performance, and the ability to maintain defensible NDC-level differentiation (formulation, labeling, and route of administration).

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. Drugs@FDA. (Database). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm